Literature DB >> 18063401

Seroprevalence of hepatitis E virus in blood donors in Khuzestan Province, southwest Iran.

Mohammad Ali Assarehzadegan1, Ghodratollah Shakerinejad, Akram Amini, S A Rahim Rezaee.   

Abstract

OBJECTIVE: To determine the seroprevalence of hepatitis E virus (HEV) infection among volunteer blood donors in Khuzestan Province, Iran. Khuzestan is a war stricken area in the southwest of Iran, which shares a land, river, and sea border with Iraq. This region has suffered the heaviest public health system damage of all the Iranian provinces during a 25-year period of war and conflict.
METHODS: A cross-sectional study was carried out among 400 urban volunteer blood donors of the regional blood banks, from May to December 2005. Serum samples from healthy blood donors were tested for IgG anti-HEV antibody using a specific enzyme linked immunoassay (ELISA) kit.
RESULTS: The prevalence of HEV infection was found to be 11.5% (46/400). All patients were negative for anti-HIV, anti-HBV, and anti-HCV antibodies. The data indicate that 14.6% (38/260) of HEV positive subjects were male, compared to 5.7% (8/140) of females; this difference is statistically significant (risk ratio=2.6, p<0.008).
CONCLUSIONS: These findings demonstrate the high prevalence rate of anti-HEV among blood donors, particularly males.

Entities:  

Mesh:

Year:  2007        PMID: 18063401     DOI: 10.1016/j.ijid.2007.09.015

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  23 in total

Review 1.  Hepatitis E: an old infection with new implications.

Authors:  Giuseppe Marano; Stefania Vaglio; Simonetta Pupella; Giuseppina Facco; Maria Bianchi; Gabriele Calizzani; Fabio Candura; Liviana Catalano; Blandina Farina; Monica Lanzoni; Vanessa Piccinini; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2014-09-12       Impact factor: 3.443

2.  Hepatitis E virus and serum level aminotransferases in blood donors.

Authors:  Abdolreza Sotoodeh Jahromi; Morteza Pourahmad
Journal:  Rep Biochem Mol Biol       Date:  2013-10

Review 3.  Hepatitis E virus in the countries of the Middle East and North Africa region: an awareness of an infectious threat to blood safety.

Authors:  Soha Yazbek; Khalil Kreidieh; Sami Ramia
Journal:  Infection       Date:  2015-06-26       Impact factor: 3.553

Review 4.  Epidemiology of hepatitis E virus in Iran.

Authors:  Reza Taherkhani; Fatemeh Farshadpour
Journal:  World J Gastroenterol       Date:  2016-06-14       Impact factor: 5.742

5.  Seroprevalence of Hepatitis E Virus infection among volunteer blood donors in central province of Iran in 2012.

Authors:  Hassan Ehteram; Amitis Ramezani; Ali Eslamifar; Masoomeh Sofian; Mohammad Banifazl; Shahin Ghassemi; Arezoo Aghakhani; Parisa Mashayekhi
Journal:  Iran J Microbiol       Date:  2013-06

6.  Seroprevalence of hepatitis E among Iranian renal transplant recipients.

Authors:  Zakieh Rostamzadeh Khameneh; Nariman Sepehrvand; Sima Masudi
Journal:  Hepat Mon       Date:  2011-08       Impact factor: 0.660

7.  Prevalence of Hepatitis E Virus among Adults in South-West of Iran.

Authors:  Fatemeh Farshadpour; Reza Taherkhani; Manoochehr Makvandi
Journal:  Hepat Res Treat       Date:  2015-06-23

8.  Hepatitis E virus seroprevalence in HIV positive individuals in Shiraz, Southern Iran.

Authors:  Hassan Joulaei; Omid Rudgari; Nasrin Motazedian; Samaneh Gorji-Makhsous
Journal:  Iran J Microbiol       Date:  2015-04

9.  Serological investigation for hepatitis E virus infection in the patients with chronic maintenance hemodialysis from southwest of Iran.

Authors:  Omid R Zekavat; Alireza Makarem; Mohammad Y Karami; Aida Amanat; Maesoomeh Mohandes; Mojtaba Habibagahi
Journal:  Asian J Transfus Sci       Date:  2013-01

10.  Prevalence of hepatitis B and C infections and HCV genotypes among haemophilia patients in ahvaz, southwest iran.

Authors:  Mohammad Ali Assarehzadegan; Mehri Ghafourian Boroujerdnia; Khodamorad Zandian
Journal:  Iran Red Crescent Med J       Date:  2012-08-30       Impact factor: 0.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.